We have studied the expression of the beta2-integrin Mac-1 (CD11b) on mononuclear cells in 48 patients with AML at first diagnosis by flow cytometry using a direct fluorescein-conjugated antibody. A case was defined as positive if more than 20% of the cells expressed Mac-1.

Results of our meta-analysis showed that compared with AML patients with CD11b negativity, AML patients with CD11b positivity are associated with lower CRR, shorter OS, but has no significant effect on DFS.

cd11b属于细胞黏附分子整合素，与细胞的黏附与迁移功能有关，其高表达与aml髓外浸润及预后有密切联系。 有文献报道CD11b常表达于M 5 亚型白血病，本研究CD11b在各白血病亚型中的表达与文献报道一致，但CD11b + AML与CD11b - AML患者CR率差异无统计学意义（ P >0.05 ...

2024年7月2日 · In four AML cell lines, HL-60, ML-2, MOLM-13 and MV4-11, we analyzed CD11b and annexin-V for up to 8 days, observing a progressive increase in CD11b expression, achieving differentiation...

2024年3月13日 · CD11b 在白血病的原始细胞、自然杀伤细胞、成熟的单核细胞、粒细胞中表达，分布在骨髓的单核细胞表面，介导间质和细胞之间的黏附，在造血细胞发育过程中，原单核细胞以及髓系祖细胞阶段能够最早检测到CD11b，且随着细胞的分化，CD11b表达降低。CD11b高表达 ...

2015年8月26日 · CD11b positivity could predict a poor prognosis for AML patients. Thus, CD11b expression level might be considered a prognostic biomarker for AML patients.

2006年3月20日 · We have studied the expression of the β 2-integrin Mac-1 (CD11b) on mononuclear cells in 48 patients with AML at first diagnosis by flow cytometry using a direct fluorescein-conjugated antibody. A case was defined as positive if more than 20% of the cells expressed Mac-1.

Objective: Myeloid-derived suppressor cells (MDSCs) facilitate tumor growth and development by suppressing T cell function; however, their role in acute myeloid leukemia (AML) remains unclear. Here, we investigated the immunosuppressive role and prognostic value of …

2015年8月26日 · Study results on the prognostic value of CD11b for acute myeloid leukemia (AML) patients are inconsistent. An up-to-date meta-analysis was conducted to assess the prognostic value of CD11b expression level for AML patients.

方法 采用碱性磷酸酶抗碱性磷酸酶复合物法（APAAP），测定80例AML患者细胞膜表面CD11b的阳性表达。 结果 CD11b＋AML缓解率（44.4％）明显低于D11b－AML缓解率（73.8％）（P＜0.05），CD11b＋AML患者平均生存期明显低于CD11b－AML患者（P＜0.01），且与年龄、白细胞数、细胞遗传学异常等因素无关。 结论 CD11b表达是AML预后不良的特征之一。